Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

Novel therapies are undergoing clinical trials, for example, the Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for the treatment of therapy‐resistant melanomas. Unfortunately, our data show that this combination elicits a heterogeneous response in a panel of melanoma cell lines includi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mol Syst Biol
Huvudupphovsmän: Azimi, Alireza, Caramuta, Stefano, Seashore‐Ludlow, Brinton, Boström, Johan, Robinson, Jonathan L, Edfors, Fredrik, Tuominen, Rainer, Kemper, Kristel, Krijgsman, Oscar, Peeper, Daniel S, Nielsen, Jens, Hansson, Johan, Egyhazi Brage, Suzanne, Altun, Mikael, Uhlen, Mathias, Maddalo, Gianluca
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2018
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836539/
https://ncbi.nlm.nih.gov/pubmed/29507054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/msb.20177858
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk